In NSCLC, VEGF-A response to hypoxia may differ between squamous cell and adenocarcinoma histology

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 4729-4736

  Eilertsen, Marte ^a   Pettersen, Ingvild ^a   Andersen, Sigve ^a,b   Martinez, Inigo ^a   Donnem, Tom ^a,b   Busund, Lill Tove ^a,b   Bremnes, Roy M ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Adenocarcinoma; Hypoxia; NSCLC; Squamous cell carcinoma; VEGF A; VEGF C

Indexed keywords

VASCULOTROPIN A; VASCULOTROPIN C;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CANCER SURVIVAL; CARCINOMA CELL; CELL HYPOXIA; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SUPERNATANT; TISSUE MICROARRAY;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; TISSUE ARRAY ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84872668949     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60(5): 277-300, 2010.
2. Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O'Byrne KJ, Koong AC and Giaccia AJ: An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 12(5): 1507-1514, 2006.
3. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144(5): 646-674, 2011.
4. Werynska B, Dziegiel P and Jankowska R: Role of lymphangiogenesis in lung cancer. Folia Histochem Cytobiol 47(3): 333-342, 2009.
5. Stacker SA and Achen MG: From anti-angiogenesis to antilymphangiogenesis: emerging trends in cancer therapy. Lymphat Res Biol 6(3-4): 165-172, 2008.
6. Adams RH and Alitalo K: Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8(6): 464-478, 2007.
7. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N and Alitalo K: Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 16(13): 3898-3911, 1997.
8. Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K and Stacker SA: Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95(2): 548-553, 1998.
9. Langer CJ, Besse B, Gualberto A, Brambilla E and Soria JC: The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 28(26): 5311-5320, 2010.
10. Hirsch FR, Wynes MW, Gandara DR and Bunn PA: The tissue is the issue: Personalized medicine for non-small cell lung cancer. Clin Cancer Res 16(20): 4909-4911, 2010.
11. Bremnes RM, Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, Camps C, Marinez I and Busund LT: The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 6(1): 209-217, 2011.
12. Kalluri R and Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 6(5): 392-401, 2006.
13. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK and Seed B: Tumor induction of VEGF promoter activity in stromal cells. Cell 94(6): 715-725, 1998.
14. Underwood JCE: General and Systematic Pathology: Churchill Livingstone, 2004.
15. Travis WD, Colby TV, Corrin B, Shimosato Y and Brambilla E: Histological typing of lung and pleural tumours (WHO. World Health Organization. International Histological Classification of Tumours), Springer-Verlag, 1999.
16. Donnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, Nilsen MN, Busund LT and Bremnes RM: Inverse prognostic impact of angiogenic marker expression in tumor cells versusstromal cells in non small cell lung cancer. Clin Cancer Res 13(22 Pt 1): 6649-6657, 2007.
17. Enholm B, Paavonen K, Ristimaki A, Kumar V, Gunji Y, Klefstrom J, Kivinen L, Laiho M, Olofsson B, Joukov V, Eriksson U and Alitalo K: Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 14(20): 2475-2483, 1997.
18. Boussat S, Eddahibi S, Coste A, Fataccioli V, Gouge M, Housset B, Adnot S and Maitre B: Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol 279(2):L371-378, 2000.
19. Simiantonaki N, Jayasinghe C, Michel-Schmidt R, Peters K, Hermanns MI and Kirkpatrick CJ: Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines. Int J Oncol 32(3): 585-592, 2008.
20. Fukuyama T, Ichiki Y, Yamada S, Shigematsu Y, Baba T, Nagata Y, Mizukami M, Sugaya M, Takenoyama M, Hanagiri T, Sugio K and Yasumoto K: Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/ immunological responses both in vivo and invitro. Cancer Sci 98(7): 1048-1054, 2007.
21. Koshikawa N, Iyozumi A, Gassmann M and Takenaga K: Constitutive up-regulation of hypoxia-inducible factor-1alpha mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure. Oncogene 22(43): 6717-6724, 2003.
22. Min Y, Ghose S, Boelte K, Li J, Yang L and Lin PC: C/EBP-delta regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1alpha. Oncogene 30(49):4901-4909, 2011.
23. Stacker SA, Achen MG, Jussila L, Baldwin ME and Alitalo K: Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2(8):573-583, 2002.
24. Jain RK: Delivery of molecular and cellular medicine to solid tumors. J Control Release 53(1-3): 49-67, 1998.
25. Pajares MJ, Agorreta J, Larrayoz M, Vesin A, Ezponda T, Zudaire I, Torre W, Lozano MD, Brambilla E, Brambilla C, Wistuba, II, Behrens C, Timsit JF, Pio R, Field JK and Montuenga LM: Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol 30(10): 1129-1136, 2012.
26. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T and Uchida Y: Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 97(2): 457-464, 2003.
27. Ogawa E, Takenaka K, Yanagihara K, Kurozumi M, Manabe T, Wada H and Tanaka F: Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients. Br J Cancer 91(3): 498-503, 2004.
28. Renyi-Vamos F, Tovari J, Fillinger J, Timar J, Paku S, Kenessey I, Ostoros G, Agocs L, Soltesz I and Dome B: Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res 11(20): 7344-7353, 2005.
29. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y and Yasumoto K: Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 115(5): 1007-1014, 1998.
30. Ozbudak IH, Ozbilim G, Kucukosmanoglu I, Dertsiz L and Demircan A: Vascular endothelial growth factor expression and neovascularization in non-small cell lung carcinoma. Int J Surg Pathol 17(5): 390-395, 2009.
31. Dagnon K, Heudes D, Bernaudin JF and Callard P: Computerized morphometric analysis of microvasculature in non-small cell lung carcinoma. Microvasc Res 75(1): 112-118, 2008.
32. Lee CH, Lee MK, Kang CD, Kim YD, Park DY, Kim JY, Sol MY and Suh KS: Differential expression of hypoxia inducible factor-1 alpha and tumor cell proliferation between squamous cell carcinomas and adenocarcinomas among operable non-small cell lung carcinomas. J Korean Med Sci 18(2): 196-203, 2003.
33. Andersen S, Eilertsen M, Donnem T, Al-Shibli K, Al-Saad S, Busund LT and Bremnes RM: Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer 72(3): 294-302, 2011.
34. Tamura M, Oda M, Tsunezuka Y, Matsumoto I, Kawakami K, Ohta Y and Watanabe G: Chest CT and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cell lung cancer. Chest 126(2): 342-346, 2004.
35. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, 3rd, Gaudreault J, Damico LA, Holmgren E and Kabbinavar F: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22(11): 2184-2191, 2004.